Physician profile
Loreta Garretson
NPI 1124372677
$7,824.22
in general payments reported to CMS, 2019-2025
61 companies · $1,069 in 2025
The $1,069 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $501 · 2020: $359 · 2021: $629 · 2022: $1,619 · 2023: $2,002 · 2024: $1,645 · 2025: $1,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,468 · Education: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,467.65 |
| Education | $247.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $491.56 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Astrazeneca Pharmaceuticals Lp | $473.00 | 2019-2025 | Enhertu, Imfinzi, Calquence |
| Novartis Pharmaceuticals Corporation | $432.19 | 2021-2025 | |
| Celgene Corporation | $423.56 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Merck Sharp & Dohme LLC | $371.66 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $351.07 | 2020-2025 | Enhertu, Injectafer |
| Pfizer INC. | $333.38 | 2020-2025 | |
| Seagen INC. | $330.92 | 2019-2023 | Adcetris, Tukysa, Padcev |
| Incyte Corporation | $309.99 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Eisai INC. | $307.81 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $270.25 | 2019-2025 | |
| Genentech USA, INC. | $252.78 | 2019-2025 | Venclexta, Polivy, Lunsumio |
| Pharmacyclics LLC, An Abbvie Company | $240.91 | 2019-2023 | Imbruvica |
| Lilly USA, LLC | $220.75 | 2019-2024 | Jaypirca, Verzenio, Retevmo |
| Astellas Pharma US INC | $217.79 | 2019-2025 | Padcev |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $190.52 | 2022-2025 | Darzalex, Tecvayli, Talvey |
| Gilead Sciences, INC. | $182.40 | 2022-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $173.57 | 2023-2025 | Zejula, Jemperli, Ojjaara |
| Amgen INC. | $173.23 | 2019-2023 | Nplate, Xgeva |
| Aveo Pharmaceuticals, INC. | $159.96 | 2022-2025 | |
| Abbvie INC. | $149.81 | 2019-2025 | |
| Taiho Oncology, INC. | $132.33 | 2019-2025 | |
| Boston Scientific Corporation | $121.32 | 2023 | |
| Emd Serono, INC. | $106.06 | 2024-2025 | |
| Beigene USA, INC. | $100.81 | 2023 | Brukinsa |
| Exelixis INC. | $81.41 | 2019-2025 | Cabometyx |
| Genmab U.S., INC. | $78.76 | 2022-2024 | Tivdak, Epkinly |
| Puma Biotechnology, INC. | $75.89 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $66.65 | 2020-2023 | Libtayo |
| Dendreon Pharmaceuticals LLC | $64.82 | 2020-2024 | Provenge |
| Adc Therapeutics America, INC. | $59.14 | 2023-2024 | |
| Servier Pharmaceuticals LLC | $54.33 | 2024-2025 | |
| Kite Pharma, INC. | $52.68 | 2023-2025 | Yescarta |
| Takeda Pharmaceuticals U.S.A., INC. | $50.96 | 2022-2024 | Ninlaro, Fruzaqla |
| Ipsen Biopharmaceuticals, INC | $50.65 | 2019-2021 | |
| Beone Medicines USA, INC. | $46.67 | 2025 | Tevimbra, Brukinsa |
| Sumitomo Pharma America, INC. | $45.54 | 2023-2024 | Orgovyx |
| Sobi, INC | $45.49 | 2022-2025 | |
| Karyopharm Therapeutics INC. | $40.70 | 2024-2025 | Xpovio |
| Novocure INC. | $39.82 | 2024-2025 | Optune Gio, Optune Lua (Novottf-200t) |
| Foundation Medicine, INC. | $37.67 | 2020 | |
| Myovant Sciences INC. | $36.31 | 2022 | |
| Pharmacosmos Therapeutics INC. | $32.81 | 2023 | Monoferric |
| Mirati Therapeutics, INC. | $31.70 | 2023-2024 | Krazati |
| Tersera Therapeutics LLC | $31.33 | 2024-2025 | Zoladex |
| Jazz Pharmaceuticals INC. | $31.19 | 2024 | |
| Tempus Ai, INC | $22.08 | 2024 | Xt Cdx |
| Immunocore Limited | $20.20 | 2025 | Kimmtrak |
| Blue Earth Diagnostics | $20.17 | 2022 | |
| Array Biopharma INC | $17.98 | 2022 | |
| Rigel Pharmaceuticals, INC. | $17.86 | 2023 | Rezlidhia, Tavalisse |
| Legend Biotech USA INC. | $17.01 | 2025 | Carvykti |
| Menarini Silicon Biosystems, INC. | $16.94 | 2025 | |
| Progenics Pharmaceuticals, INC. | $16.88 | 2023 | Pylarify |
| Stemline Therapeutics INC. | $16.73 | 2025 | Orserdu |
| Pharmaessentia USA Corporation | $16.26 | 2024 | Besremi |
| Alexion Pharmaceuticals, INC. | $14.90 | 2025 | Ultomiris |
| Genzyme Corporation | $14.44 | 2021 | |
| Blueprint Medicines Corporation | $13.91 | 2024 | Ayvakit |
| Clovis Oncology, INC. | $13.78 | 2019 | |
| Coherus Oncology, INC. | $12.93 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Loreta Garretson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.